Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jatt Acquisition Corp Cl A (JATT)

Jatt Acquisition Corp Cl A (JATT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,760
  • Shares Outstanding, K 17,250
  • Annual Sales, $ 0 K
  • Annual Income, $ 6,850 K
  • 60-Month Beta 0.00
  • Price/Sales N/A
  • Price/Cash Flow 20.55
  • Price/Book N/A
Trade JATT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.80 +4.62%
on 03/20/23
12.38 -34.09%
on 03/16/23
-2.29 (-21.91%)
since 02/15/23
3-Month
7.80 +4.62%
on 03/20/23
12.38 -34.09%
on 03/16/23
-2.04 (-20.00%)
since 12/13/22
52-Week
7.80 +4.62%
on 03/20/23
12.38 -34.09%
on 03/16/23
-1.74 (-17.58%)
since 03/17/22

Most Recent Stories

More News
Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business...

JATT : 8.16 (-24.09%)
JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura...

JATT : 8.16 (-24.09%)
JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited

JATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class...

JATT : 8.16 (-24.09%)
JATT Acquisition Corp’s Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC

JATT Acquisition Corp (NYSE: “JATT”), the publicly traded special purpose acquisition company (“SPAC”), has today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared...

JATT : 8.16 (-24.09%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CDK, JATT, DHAC, MBII

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CDK : 54.76 (-0.15%)
JATT : 8.16 (-24.09%)
DHAC : 12.01 (unch)
MBII : 0.7981 (-20.19%)
JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company

Zura Bio Limited (“Zura Bio”), a clinical-stage biotechnology company focused on developing novel medicines for immune disorders, and JATT Acquisition Corp. (“JATT”) (NYSE: JATT, JATT.U, JATT.WS),...

JATT : 8.16 (-24.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

JATT Acquisition Corp. entered into a definitive merger agreement for a business combination with Zura Bio Limited.

See More

Key Turning Points

3rd Resistance Point 12.56
2nd Resistance Point 11.53
1st Resistance Point 9.85
Last Price 8.16
1st Support Level 7.14
2nd Support Level 6.11
3rd Support Level 4.43

See More

52-Week High 12.38
Fibonacci 61.8% 10.63
Fibonacci 50% 10.09
Fibonacci 38.2% 9.55
Last Price 8.16
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar